Conatus Pharmaceutic (CNAT) 2.02 $CNAT Conatus to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 12:14 PM

Conatus Pharmaceutic (CNAT) 2.02 $CNAT

Conatus to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meetings with invited institutional investors. The company will post a current company overview presentation in the Investors section of its website at www.conatuspharma.com.
CNAT: 2.02 (-0.11)

Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:32AM CDT
Conatus Pharmaceuticals (CNAT) reported first-quarter 2016 loss of 35 cents per share, in line with the Zacks Consensus Estimate.
VTL: 6.62 (-0.49), ANIP: 55.07 (-1.20), CNAT: 2.02 (-0.11), RTRX: 17.93 (-0.56)

Conatus' (CNAT) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:30AM CDT
Conatus' first-quarter 2016 loss of 35 cents per share came in line with consensus estimates.
CNAT: 2.02 (-0.11)

Conatus reports 1Q loss
Automated Insights - Thu May 05, 6:40AM CDT
SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $7.3 million in its first quarter.
CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Thu May 05, 6:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs. After the market close yesterday, the company announced top-line results from the second stage of its Phase 2 Liver Cirrhosis trial. A conference call and webcast are scheduled for 8:00 a.m. ET today, as detailed below, to discuss both the trial results and financial results.
CNAT: 2.02 (-0.11)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.17 (-1.46), BIIB: 232.23 (-6.39), CNAT: 2.02 (-0.11), AMGN: 147.75 (-4.52), RPRX: 1.55 (-0.15), JNJ: 116.20 (-1.18), GILD: 81.10 (-2.27), GWPH: 83.08 (-6.06), GERN: 2.61 (-0.14), AVEO: 0.95 (-0.03), ICPT: 146.29 (-7.97), AGIO: 46.08 (-2.42), NVS: 78.20 (-2.47)

Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 46.70 (-1.20), IPXL: 29.25 (-1.08), CNAT: 2.02 (-0.11), JAZZ: 139.55 (-5.45)

Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Conatus will host a conference call and audio webcast at 8:00 a.m. Eastern Time on Thursday, May 5, 2016, to discuss the financial results and provide a corporate update.
CNAT: 2.02 (-0.11)

Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
GlobeNewswire - Mon Apr 18, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score greater-than or equal to15," was delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan. The presentation visuals are available in the Clinical Data section of the Conatus website at www.conatuspharma.com.
CNAT: 2.02 (-0.11)

Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016.
CNAT: 2.02 (-0.11)

Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities
ACCESSWIRE - Wed Apr 06, 11:25AM CDT
MIAMI, FL / ACCESSWIRE / April 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TRTC, NETE, SFOR, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
VCRA: 12.19 (-0.22), CNAT: 2.02 (-0.11)

Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company's website at www.conatuspharma.com.
CNAT: 2.02 (-0.11)

Penny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016
ACCESSWIRE - Mon Apr 04, 10:43AM CDT
MIAMI, FL / ACCESSWIRE / April 4, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. ZFGN, CNAT, CRC, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
ZFGN: 5.94 (-0.34), CRC: 13.43 (-1.09), CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Appoints Edward F. Smith III as Senior Vice President, Regulatory Affairs and Quality Assurance
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Edward F. Smith III, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance.
CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Announces Acceptance of Abstracts for EASL Meeting
GlobeNewswire - Wed Mar 30, 6:30AM CDT
- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data -
CNAT: 2.02 (-0.11)

Conatus' Loss Narrower than Expected, Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 8:00AM CST
Conatus Pharmaceuticals (CNAT) reported narrower-than-expected fourth-quarter 2015 loss of 30 cents per share.
CNAT: 2.02 (-0.11), BXLT: 46.02 (-0.18), ANIK: 50.09 (-1.01)

Can Conatus (CNAT) Surprise Estimates in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 9:10AM CST
Conatus Pharmaceuticals (CNAT), which is scheduled to report fourth-quarter 2015 results on Mar 9, delivered a positive earnings surprise of 13.89% last quarter.
BDSI: 2.23 (-0.16), ALNY: 54.01 (-2.94), GILD: 81.10 (-2.27), CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) FDA has Granted Fast Track Designation for Emricasan Analyst Comments
ACCESSWIRE - Tue Feb 09, 8:06AM CST
SAN DIEGO, CA / ACCESSWIRE / February 9, 2016 / Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) a biotechnology company focused on the development and commercialization of medicines to treat liver disease, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on additional communications with the FDA recommending single-etiology clinical trials, the company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations. The Fast Track program provides for greater access to FDA to facilitate development and expedite review of drugs that have demonstrated the potential to treat serious or life-threatening conditions.
CNAT: 2.02 (-0.11)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.02 (-0.11), CORT: 5.20 (-0.27), PCRX: 38.97 (-1.02), BIOD: 0.30 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....